Globus Medical shares jumped 5.1% to $79.23 in the last trading session on higher-than-average volume, driven by investor optimism following the company's solid first-quarter 2026 performance. The medical device company posted adjusted earnings per share of $1.12 and revenues of $759.9 million, both surpassing Zacks Consensus Estimates. The consensus EPS estimate for the upcoming quarter has been revised 2.5% higher over the last 30 days, and the stock currently carries a Zacks Rank of 2, or Buy. Lucid Diagnostics, another stock in the Zacks Medical - Instruments industry, rose 9.9% to $1.08 in the same session.
Globus MedicalGlobus Medical reported strong Q1 earnings and revenue that beat estimates, driving the stock up.
Lucid Diagnostics Inc